At 7 years old, Kinlee Johnson was an avid reader. She earned good grades in school and loved playing softball.
But during a tournament, Kinlee began to struggle. At first, her parents thought she was sick from playing ball all day in the heat. Soon they knew it was something more serious.
Kinlee visited an eye doctor. He told her she just needed bifocals. Kinlee’s mom questioned that diagnosis.
But before they could visit a specialist, Kinlee got very sick, very fast. Doctors at a local hospital diagnosed a brain tumor called medulloblastoma.
![Kinlee Johnson at age 7](/content/sites/www/en_US/home/about-st-jude/stories/making-a-difference/patient-story-kinlee-johnson/jcr:content/par-1/cnt_row/par-1/cnt_column/par-1/cnt_image.img.16.medium.jpg/1711484484870.jpg)
Kinlee Johnson was only 7 years old when she began showing symptoms of medulloblastoma. She enrolled in the SJMB12 clinical trial at St. Jude. It was the first to assign treatment based on the type of medulloblastoma a child has.
Surgeons removed Kinlee’s brain tumor. Then they wanted her to begin conventional x-ray beam radiation and chemotherapy. Kinlee and her family had a decision to make.
They had heard about the SJMB12 clinical trial at St. Jude Children’s Research Hospital. This clinical trial was the first to assign treatment based on the type of medulloblastoma a child has. The clinical trial also used proton therapy, which targets the tumor precisely, sparing healthy tissue and causing fewer side effects.
“That was one of our big deciding factors,” says Kinlee’s mom, Nicole Johnson. “Kinlee’s clinical trial at St. Jude was the absolute best for our daughter at that time.”
At St. Jude, Kinlee’s medical team was able to classify her medulloblastoma as belonging to the WNT group. This was a huge relief to Kinlee’s parents, because the WNT group is the most curable of the medulloblastoma types.
![Kinlee Johnson](/content/sites/www/en_US/home/about-st-jude/stories/making-a-difference/patient-story-kinlee-johnson/jcr:content/par-1/cnt_row/par-1/cnt_column/par-1/cnt_image_152565188.img.16.medium.jpg/1711484722852.jpg)
At St. Jude, Kinlee Johnson received the care she needed to survive and thrive after a brain tumor diagnosis.
Because of WNT’s high cure rate, St. Jude doctors proposed less radiation and less chemotherapy for Kinlee than has traditionally been used for patients with medulloblastoma. This meant that Kinlee was among the first patients to receive lower-dose therapy for her brain cancer.
Today, Kinlee is a happy, healthy teen. She still loves to read. Still loves softball. She has also started tumbling classes, and she is in the gifted program at her school.
Kinlee advises other eligible patients to consider enrolling in clinical trials.
“I would definitely recommend one,” she says.
Visit the Together by St. Jude™ online resource to find information and support for families facing childhood cancer and other illnesses.
More patient stories
-
Insights Learned Through Cancer Experience Now Help Others
St. Jude survivor Tristan Elsener has survived multiple bouts of cancer. He and his family have gained insights that can help others. Learn about the Caregivers Share podcast.
-
Research may help Camille take her first steps
Research conducted by the Center for Experimental Neurotherapeutics may help patients like Camille, who has type 2 spinal muscular atrophy, gain the ability to walk.
-
Participating in clinical trials to help cure the next person
Patients like Corey Luellen have benefitted from gene editing for sickle cell disease. Luellen participated in a clinical trial for the treatment because he wanted to help others.
-
Patient finds support, help and hope for Friedrich’s ataxia
Taylor Hurdle is taking part in a clinical trial for Friedreich’s ataxia at St. Jude Children’s Research Hospital.
-
Patient reflects on 60th anniversary as childhood cancer survivor
Patient reflects on her 60th anniversary as a childhood cancer survivor
-
From Pain Crises to Good Vibes
Rashawn Hendrix
-
Family chooses St. Jude because of SAMD9/SAMD9L researcher
Family chooses St. Jude for care because of its expertise in SAMD9/SAMD9L syndrome.
-
Molecular diagnostics give Fletcher what some thought impossible: a diagnosis and treatment plan
Molecular diagnostics give Fletcher Fazenbaker what some thought impossible: a diagnosis and treatment plan for infant-type hemispheric glioma (IHG), a subtype of high-grade glioma — a rare brain tumor — that was not classified by the World Health Organization’s brain tumor classification guide until 2021
-
Surviving childhood cancer is just the beginning of Darshana’s story
Darshana Magan survived cancer 30 years ago, but her treatment caused long-term health issues. Read how she cares for her health and encourages other survivors.
-
Sickle cell disease education and support help Jayden excel
Jayden's care team at St. Jude is helping him manage and understand his sickle cell disease. Learn more
-
Scan-tastic! St. Jude helps Zara succeed
St. Jude child life specialists help patients understand the MRI scanning process to make it easier for them, and some patients are able to stay still enough for scans that anesthesia isn't needed.
-
Teen climbs new heights after bone cancer
Doctors at St. Jude Children's Research Hospital were able to save Micah Winkle's leg from bone cancer, but it was up to the teen to discover alternatives to the contact sports he had played before his cancer diagnosis. Find out more.
-
Limiting the side effects of treatment: Proton Therapy provides focused radiation
St. Jude has the world’s first proton therapy center dedicated to childhood cancer. Patients come from all over to receive treatment. One such patient is Brianna Gonzales.